LENZ Stock Forecast & Price Target

LENZ Therapeutics is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. With a targeted VIZZ launch in presbyopia patients and over 46K filled prescriptions across 10K unique ECP prescribers through the first quarter of 2026, we believe that the company's revenue growth potential is high, particularly with the recent initiation of a DTC campaign featuring Sarah Jessica Parker. Additionally, with a planned expanded sales force expected to be fully deployed by the end of the second quarter of 2026, we see potential for even greater prescription depth over time. With a price target of $38 per share, based on an equally-weighted composite of a 25x multiple of taxed and diluted 2034 EPS and an NPV discounted cash flow, we maintain our Buy rating on LENZ Therapeutics and highlight the potential risks to our investment thesis, such as failure to achieve peak commercial revenue estimates and shortage of capital resources for operations.

LENZ Therapeutics is banking on the potential success of their novel pupil-selective miotic eye drop VIZZ, however, the initial launch trajectory has not met expectations and revenue estimates have been adjusted downward. Additionally, the company continues to report significant operating expenses and net losses, possibly indicating potential financial strains in the future. While the company does have a strong sales team and DTC campaign, there are concerns about potential competition and the company's ability to achieve peak commercial revenue.